Summary

Prohibits the HHS Secretary from entering into or approving drug manufacturer agreements that allow Federally Qualified Health Centers (FQHCs) to be charged more than the 340B ceiling price at the point of purchase. It also bars arrangements where an FQHC pays above the ceiling price at purchase and is later reimbursed or reconciled (rebates, reimbursements, or other payments). One other, non‑substantive provision sets a short title for the Act. The pricing restriction is effective on enactment and applies to drugs purchased on or after enactment and to determinations about whether existing agreements comply with 340B starting at enactment.

• Prevents HHS from approving manufacturer agreements that let Federally Qualified Health Centers be charged more than the 340B ceiling price at the point of purchase.
• Prohibits arrangements where FQHCs pay over the ceiling price at purchase and receive later reconciliation to make up the difference.
• Applies immediately on enactment to drug purchases on or after enactment and to reviews of existing agreements.
• Does not change how the 340B ceiling price is computed; it restricts contract and payment practices relative to that ceiling.
• Contains one non‑substantive short‑title provision that does not affect program operations or funding.
• Imposes a regulatory limit rather than providing new funding or authorizing new spending.
• Shifts the compliance question to HHS: agreements that enable over‑charging at point of sale would be impermissible under federal law.